194 related articles for article (PubMed ID: 37086103)
1. Intracerebroventricular administration for delivery of antiseizure therapeutics: Challenges and opportunities.
Fahoum F; Eyal S
Epilepsia; 2023 Jul; 64(7):1750-1765. PubMed ID: 37086103
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnological advances in the treatment of epilepsy: a comprehensive review.
Rai G; Sharma S; Bhasin J; Aggarwal K; Ahuja A; Dang S
Nanotechnology; 2024 Jan; 35(15):. PubMed ID: 38194705
[TBL] [Abstract][Full Text] [Related]
3. Models in research of pharmacoresistant epilepsy: present and future in development of antiepileptic drugs.
Kovács R; Heinemann U
Curr Med Chem; 2014; 21(6):689-703. PubMed ID: 24251565
[TBL] [Abstract][Full Text] [Related]
4. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy.
Rambeck B; Jürgens UH; May TW; Pannek HW; Behne F; Ebner A; Gorji A; Straub H; Speckmann EJ; Pohlmann-Eden B; Löscher W
Epilepsia; 2006 Apr; 47(4):681-94. PubMed ID: 16650134
[TBL] [Abstract][Full Text] [Related]
5. Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice.
Glascock JJ; Osman EY; Coady TH; Rose FF; Shababi M; Lorson CL
J Vis Exp; 2011 Oct; (56):. PubMed ID: 21988897
[TBL] [Abstract][Full Text] [Related]
6. Transependymal Cerebrospinal Fluid Flow: Opportunity for Drug Delivery?
Casaca-Carreira J; Temel Y; Hescham SA; Jahanshahi A
Mol Neurobiol; 2018 Apr; 55(4):2780-2788. PubMed ID: 28455692
[TBL] [Abstract][Full Text] [Related]
7. CNS transporters and drug delivery in epilepsy.
Potschka H; Luna-Munguia H
Curr Pharm Des; 2014; 20(10):1534-42. PubMed ID: 23789955
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal delivery of protein therapeutics to the brain: a critical reassessment.
Calias P; Banks WA; Begley D; Scarpa M; Dickson P
Pharmacol Ther; 2014 Nov; 144(2):114-22. PubMed ID: 24854599
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of currently used antiseizure drugs.
Sills GJ; Rogawski MA
Neuropharmacology; 2020 May; 168():107966. PubMed ID: 32120063
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal application of ethosuximide is highly efficient in suppressing seizures in a genetic model of absence epilepsy.
Buschhoff AS; Scherließ R; de Mooij-van Malsen JG; Schiffelholz T; Stephani U; Wulff P
Epilepsy Res; 2022 Aug; 184():106967. PubMed ID: 35772325
[TBL] [Abstract][Full Text] [Related]
11. Blood-brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approaches.
Marchi N; Granata T; Ghosh C; Janigro D
Epilepsia; 2012 Nov; 53(11):1877-86. PubMed ID: 22905812
[TBL] [Abstract][Full Text] [Related]
12. Potential new methods for antiepileptic drug delivery.
Fisher RS; Ho J
CNS Drugs; 2002; 16(9):579-93. PubMed ID: 12153331
[TBL] [Abstract][Full Text] [Related]
13. Neurovascular Drug Biotransformation Machinery in Focal Human Epilepsies: Brain CYP3A4 Correlates with Seizure Frequency and Antiepileptic Drug Therapy.
Williams S; Hossain M; Ferguson L; Busch RM; Marchi N; Gonzalez-Martinez J; Perucca E; Najm IM; Ghosh C
Mol Neurobiol; 2019 Dec; 56(12):8392-8407. PubMed ID: 31243719
[TBL] [Abstract][Full Text] [Related]
14. CNS drug delivery systems: novel approaches.
Pathan SA; Iqbal Z; Zaidi SM; Talegaonkar S; Vohra D; Jain GK; Azeem A; Jain N; Lalani JR; Khar RK; Ahmad FJ
Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):71-89. PubMed ID: 19149731
[TBL] [Abstract][Full Text] [Related]
15. Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics.
Kumar H; Mishra G; Sharma AK; Gothwal A; Kesharwani P; Gupta U
Pharm Nanotechnol; 2017; 5(3):203-214. PubMed ID: 28521670
[TBL] [Abstract][Full Text] [Related]
16. Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies.
Gernert M; Feja M
Pharmaceutics; 2020 Nov; 12(12):. PubMed ID: 33255396
[TBL] [Abstract][Full Text] [Related]
17. The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy.
Brandt C; Hillmann P; Noack A; Römermann K; Öhler LA; Rageot D; Beaufils F; Melone A; Sele AM; Wymann MP; Fabbro D; Löscher W
Neuropharmacology; 2018 Sep; 140():107-120. PubMed ID: 30081001
[TBL] [Abstract][Full Text] [Related]
18. Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy.
Liu JY; Thom M; Catarino CB; Martinian L; Figarella-Branger D; Bartolomei F; Koepp M; Sisodiya SM
Brain; 2012 Oct; 135(Pt 10):3115-33. PubMed ID: 22750659
[TBL] [Abstract][Full Text] [Related]
19. Insights into Potential Targets for Therapeutic Intervention in Epilepsy.
Zavala-Tecuapetla C; Cuellar-Herrera M; Luna-Munguia H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202963
[TBL] [Abstract][Full Text] [Related]
20. Safety Evaluation of CNS Administered Biologics-Study Design, Data Interpretation, and Translation to the Clinic.
Vuillemenot BR; Korte S; Wright TL; Adams EL; Boyd RB; Butt MT
Toxicol Sci; 2016 Jul; 152(1):3-9. PubMed ID: 27354708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
